Dry Needling and Botulinum Toxin in the Management of Poststroke Spasticity
Status:
Completed
Trial end date:
2018-03-30
Target enrollment:
Participant gender:
Summary
Stroke is a clinical picture that can result in loss of motor, sensory and cognitive
functions or coma. Approximately 75% of stroke survivors develop disability and one of the
causes of disability is the presence of spasticity. Effective treatment of spasticity
accelerates functional recovery. Botulinum toxin type A (BTX-A) injection is a safe and
effective method in the management of focal spasticity. As its effects over central and
peripheral nervous system have been understood, dry needling has been recently introduced as
the novel treatment of spasticity after stroke in clinical practice. Studies evaluating the
efficacy of dry needling in the treatment of spasticity are limited in the literature and
there is no data on the long-term efficacy of dry needling in current studies. On the other
hand, the effects of dry needling when combined with other antispastic treatment modalities
have not been investigated yet. In this study, the antispastic efficacy of dry needling
applied with BTX-A injection was investigated.
Phase:
N/A
Details
Lead Sponsor:
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A onabotulinumtoxinA